Humana's Surge in Medicare Advantage Ratings: Implications for Insurers

Humana has reported a significant increase in its Medicare Advantage quality ratings for 2027, positioning it favorably for enhanced government bonus payments and improved earnings projections.

This development is particularly noteworthy given the broader industry context, where several other leading U.S. health insurers experienced reductions in their Medicare Advantage ratings. According to data from the Centers for Medicare & Medicaid Services (CMS), approximately 71% of enrollees in Medicare Advantage prescription drug plans are currently part of contracts rated four stars or higher for 2027. The CMS rating system, based on a five-star scale, is a crucial determinant of not only government bonuses but also the plans’ ability to attract new enrollees.

Humana's Ratings Surge

Humana distinguished itself among competitors, with an impressive 95% of its members in plans rated at least four stars. Oppenheimer's analysis shows this marked a 53% improvement over the previous year, potentially adding $3.6 billion in revenue. The increase in Humana's ratings may enhance its appeal in the Medicare Advantage market, which is significant, given the competitive landscape and the financial benefits tied to these ratings.

Challenges for Competitors

In contrast, other major providers like UnitedHealth Group and CVS Health reported a 15% decrease in their average ratings, while Elevance Health and Centene experienced declines of 10% and 9%, respectively. These downgrades have already impacted the stock market, with Humana's shares rising by about 14%, counter to the declines seen in UnitedHealth and CVS Health.

The lower ratings could also affect these insurers' financial outcomes through decreased bonus payments and potential challenges in maintaining membership numbers.

Implications and Future Prospects

Medicare Advantage plans are privately managed but government-supported, serving Americans aged 65 and older or eligible individuals with disabilities. Their performance ratings influence federal payments and enrollment opportunities. The CMS has projected over $13 billion in quality bonus payments for Medicare Advantage in 2026, underlining the financial stakes involved.

For 2027, CMS highlighted that approximately 37% of Medicare Advantage contracts achieved ratings of four stars or higher. This differs from the 71% enrollment figure, demonstrating a shift in where beneficiaries are choosing to enroll. This distinction is critical for insurance professionals to monitor due to the enrollment flexibility and potential for increased bonuses tied to higher-star ratings.

Simplified Impact Analysis

• Humana: 95% members in four-star or higher plans; potential $3.6 billion revenue boost.
• UnitedHealth/CVS Health: 15% rating drop; potential impact on shares and bonus payments.
• KFF: Estimated $13 billion in quality bonus payments for 2026.

Looking Ahead

As the Medicare open enrollment period approaches (October 15 to December 7), the star ratings will play a pivotal role in shaping Medicare Advantage insurers' financial futures and competitive strategies. UnitedHealthcare and Aetna may need to consider adjusting membership strategies or leveraging other operations to counterbalance potential declines in bonus payments.

The performance landscape detailed in the 2027 ratings will directly impact the quality bonus payments for 2028, emphasizing the ratings' critical role in the insurance carriers' strategic planning and market positioning.